Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system

Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Translational lung cancer research 2021-06, Vol.10 (6), p.2614-2624
Hauptverfasser: Bai, Shuai, Tian, Tiantian, Pacheco, Jose M., Tachihara, Motoko, Hu, Pingping, Zhang, Jiandong
Format: Artikel
Sprache:eng
Schlagworte:
Original
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2624
container_issue 6
container_start_page 2614
container_title Translational lung cancer research
container_volume 10
creator Bai, Shuai
Tian, Tiantian
Pacheco, Jose M.
Tachihara, Motoko
Hu, Pingping
Zhang, Jiandong
description
doi_str_mv 10.21037/tlcr-21-464
format Article
fullrecord <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8264309</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_8264309</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-1942c6479343a56785de982fd39bb20731ee1bd6b7a3335691d06db35a5bab63</originalsourceid><addsrcrecordid>eNpdkd9qFTEQxhdRbKm98wFyqWDq5u-e9UIora2FA3rR-2WSzPZEN8mS5ByoL-hrmWNF0JuZYb6ZHx98Xfea9Rec9WJ4XxebKWdUavmsO-WcayrlMDw_zmxD9aDYSXdeyre-75kcpVLjy-5ESD4qrfVp9_MuhH1EmnGBio6AO2AuSPCAsZI1p9kvSNJMbArGR6g-RVIzQg3HgyZ8vaZvtm8ZsTu039fk29bHnTe-plwIREcMHsD6H_sApkkkpkhLgGUhFltZ9vGBWIgWM1kbv2HLB-KgAplzCqTukNxcX_7nLOOacvXttTyWiuFV92KGpeD5n37W3d98ur_6TLdfbu-uLrfUSj5UykbJrZbDKKQApYeNcjhu-OzEaAzvB8EQmXHaDCCEUHpkrtfOCAXKgNHirPv4hF33JqCzzUqGZVqzD5AfpwR--leJfjc9pMO04VqKfmyAd08Am1MpGee_v6yffkc6HSNt49QiFb8AdfaYpA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Bai, Shuai ; Tian, Tiantian ; Pacheco, Jose M. ; Tachihara, Motoko ; Hu, Pingping ; Zhang, Jiandong</creator><creatorcontrib>Bai, Shuai ; Tian, Tiantian ; Pacheco, Jose M. ; Tachihara, Motoko ; Hu, Pingping ; Zhang, Jiandong</creatorcontrib><identifier>ISSN: 2218-6751</identifier><identifier>EISSN: 2226-4477</identifier><identifier>DOI: 10.21037/tlcr-21-464</identifier><identifier>PMID: 34295666</identifier><language>eng</language><publisher>AME Publishing Company</publisher><subject>Original</subject><ispartof>Translational lung cancer research, 2021-06, Vol.10 (6), p.2614-2624</ispartof><rights>2021 Translational Lung Cancer Research. All rights reserved. 2021 Translational Lung Cancer Research.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c427t-1942c6479343a56785de982fd39bb20731ee1bd6b7a3335691d06db35a5bab63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264309/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264309/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Bai, Shuai</creatorcontrib><creatorcontrib>Tian, Tiantian</creatorcontrib><creatorcontrib>Pacheco, Jose M.</creatorcontrib><creatorcontrib>Tachihara, Motoko</creatorcontrib><creatorcontrib>Hu, Pingping</creatorcontrib><creatorcontrib>Zhang, Jiandong</creatorcontrib><title>Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system</title><title>Translational lung cancer research</title><subject>Original</subject><issn>2218-6751</issn><issn>2226-4477</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkd9qFTEQxhdRbKm98wFyqWDq5u-e9UIora2FA3rR-2WSzPZEN8mS5ByoL-hrmWNF0JuZYb6ZHx98Xfea9Rec9WJ4XxebKWdUavmsO-WcayrlMDw_zmxD9aDYSXdeyre-75kcpVLjy-5ESD4qrfVp9_MuhH1EmnGBio6AO2AuSPCAsZI1p9kvSNJMbArGR6g-RVIzQg3HgyZ8vaZvtm8ZsTu039fk29bHnTe-plwIREcMHsD6H_sApkkkpkhLgGUhFltZ9vGBWIgWM1kbv2HLB-KgAplzCqTukNxcX_7nLOOacvXttTyWiuFV92KGpeD5n37W3d98ur_6TLdfbu-uLrfUSj5UykbJrZbDKKQApYeNcjhu-OzEaAzvB8EQmXHaDCCEUHpkrtfOCAXKgNHirPv4hF33JqCzzUqGZVqzD5AfpwR--leJfjc9pMO04VqKfmyAd08Am1MpGee_v6yffkc6HSNt49QiFb8AdfaYpA</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Bai, Shuai</creator><creator>Tian, Tiantian</creator><creator>Pacheco, Jose M.</creator><creator>Tachihara, Motoko</creator><creator>Hu, Pingping</creator><creator>Zhang, Jiandong</creator><general>AME Publishing Company</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>202106</creationdate><title>Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system</title><author>Bai, Shuai ; Tian, Tiantian ; Pacheco, Jose M. ; Tachihara, Motoko ; Hu, Pingping ; Zhang, Jiandong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-1942c6479343a56785de982fd39bb20731ee1bd6b7a3335691d06db35a5bab63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Bai, Shuai</creatorcontrib><creatorcontrib>Tian, Tiantian</creatorcontrib><creatorcontrib>Pacheco, Jose M.</creatorcontrib><creatorcontrib>Tachihara, Motoko</creatorcontrib><creatorcontrib>Hu, Pingping</creatorcontrib><creatorcontrib>Zhang, Jiandong</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational lung cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bai, Shuai</au><au>Tian, Tiantian</au><au>Pacheco, Jose M.</au><au>Tachihara, Motoko</au><au>Hu, Pingping</au><au>Zhang, Jiandong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system</atitle><jtitle>Translational lung cancer research</jtitle><date>2021-06</date><risdate>2021</risdate><volume>10</volume><issue>6</issue><spage>2614</spage><epage>2624</epage><pages>2614-2624</pages><issn>2218-6751</issn><eissn>2226-4477</eissn><pub>AME Publishing Company</pub><pmid>34295666</pmid><doi>10.21037/tlcr-21-464</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2218-6751
ispartof Translational lung cancer research, 2021-06, Vol.10 (6), p.2614-2624
issn 2218-6751
2226-4477
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8264309
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Original
title Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T19%3A31%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune-related%20adverse%20event%20profile%20of%20combination%20treatment%20of%20PD-(L)1%20checkpoint%20inhibitors%20and%20bevacizumab%20in%20non-small%20cell%20lung%20cancer%20patients:%20data%20from%20the%20FDA%20adverse%20event%20reporting%20system&rft.jtitle=Translational%20lung%20cancer%20research&rft.au=Bai,%20Shuai&rft.date=2021-06&rft.volume=10&rft.issue=6&rft.spage=2614&rft.epage=2624&rft.pages=2614-2624&rft.issn=2218-6751&rft.eissn=2226-4477&rft_id=info:doi/10.21037/tlcr-21-464&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_8264309%3C/pubmedcentral_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34295666&rfr_iscdi=true